We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




First Add-On Module Automates Cloning of DNA Sequences

By LabMedica International staff writers
Posted on 16 Dec 2015
Print article
Image: The BioXp 3200 System (Photo courtesy of Synthetic Genomics Inc. (SGI-DNA Inc.)).
Image: The BioXp 3200 System (Photo courtesy of Synthetic Genomics Inc. (SGI-DNA Inc.)).
The producer of the world's first commercial "DNA printer" is introducing a cloning module that will endow the system with the ability to synthesize and clone custom-designed DNA with an overnight instrument run.

SGI-DNA Inc., a fully owned subsidiary of Synthetic Genomics Inc. (La Jolla, CA, USA) and the manufacturer of the BioXp 3200 System for DNA synthesis, has announced the launch of beta-testing of the BioXp 3200 System Cloning Module.

The benchtop BioXp System is a genomic workstation that generates high-quality DNA from custom designed reagents. Now, with the introduction of the Cloning Module, the BioXp System has the additional capability to assemble and simultaneously deliver up to 24 DNA clones from custom DNA sequences submitted electronically. This module will enable researchers to obtain cloned de novo DNA fragments in their laboratory virtually hands-free, further automating and shortening molecular biology work flows without relying on an external service company.

To synthesis genes on the BioXp system requires custom BioXp reagents. After identifying the desired DNA sequence the researcher uploads a FASTA file to the SGIDNA secure website. The BioXp 3200 System reagents are then manufactured to the researcher's specifications. To begin the assembly reaction, the researcher loads his custom reagents onto the BioXp 3200 deck according to the deck map provided with the reagents. The BioXp connects over the Internet with the cloud to pull down the optimized protocol. The instrument prompts the beginning of the application run. DNA assembly runs generally require 12–17 hours depending on the complexity of the construct.

"It is truly exciting that the technologies we developed for simplifying molecular biology are now being automated by the BioXp System," said Dr. Daniel Gibson, vice president of DNA Technology at SGI-DNA. "The cloning module is very important as it will pave the way to help researchers streamline the study of genes and gene families at an unprecedented rate."

Related Links:

SGI-DNA Inc. (Synthetic Genomics Inc.)


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.